Skip to content

The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork

The Expression of Matrix Metalloproteinase 13(MMP13), Tissue Inhibitor of Metalloproteinases 3(TIMP13), and Calcium-sensing Receptor(CaSR) in Human Trabecular Meshwork

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02638181
Enrollment
60
Registered
2015-12-23
Start date
2013-07-31
Completion date
2015-12-31
Last updated
2017-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-angle Glaucoma

Keywords

matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3, calcium-sensing receptor, trabecular meshwork, open-angle glaucoma

Brief summary

This study was to assess the distinct expression of matrix metalloproteinase 13,tissue inhibitor of metalloproteinases 3, and calcium-sensing receptor, in human trabecular meshwork between normal and glaucomatous eyes.The expressions of matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3 and calcium-sensing receptor in the trabecular meshwork tissues were examined by streptavidin-peroxidase immunohistochemical staining method and western blot, and histological changes of trabecular meshwork were studied by Hematoxylin and Eosin staining.

Interventions

PROCEDUREtrabeculectomy

Sponsors

Lv Yingjuan
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* intraocular pressure greater than 22 mmHg with two or more medications * wide anterior chamber angle * glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect * visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry

Exclusion criteria

* the presence of any secondary form of glaucoma including exfoliation syndrome or a history of ocular trauma, etc

Design outcomes

Primary

MeasureTime frame
the expressions of matrix metalloproteinase 13 and calcium-sensing receptorone hour after operation

Secondary

MeasureTime frame
histological changes of trabecular meshworkone hour after operation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026